CoChat
Sign Up
Cited by 29Cervical Cancer and HPV ResearchWomen's cancer prevention and managementReproductive tract infections research

Cervico-Vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: high acceptability, hrHPV diversity and risk factors

Open access
Rodrigues, Luana L.S., Morgado, Mariza G., Sahasrabuddhe, Vikrant V., De Paula, Vanessa S., Oliveira, Nathália S., Chavez-Juan, Elena, Da Silva, Diane M., Kast, W. Martin +2 more·2018·Gynecologic Oncology
DOI 10.1016/j.ygyno.2018.08.004PMC PMC6151287
Open this paper in CoChat — free account

Abstract

Objective We evaluated acceptability of cervico-vaginal self-collection (CVSC) and prevalence of human papillomavirus (HPV) in Human immunodeficiency virus (HIV)-infected and HIV-uninfected women living in the Tapajós region, Amazon, Brazil. Methods Cross-sectional study recruited 153 non-indigenous women (HIV-uninfected, n = 112 and HIV-infected, n = 41) who voluntarily sought assistance in health services. Peripheral blood for HIV screening and cervical scraping (CS) for HPV detection were collected. Women who accepted to perform CVSC received instructions and individual collection kits. Risk factors for high-risk HPV genotypes (hrHPV) were identified by uni- and multivariate analyses. Results The overall acceptability of CVSC was 87%. Only HIV-infected women had cytological abnormalities (12.2%). Prevalence of any HPV and hrHPV infection was 42.9% and 47.9% for HIV-uninfected and 97.6% and 77.5% for HIV-infected women, respectively. There was significant agreement in the detection of HPV (88%, 0.76, 95% confidence interval [CI], 0.65-0.87) and hrHPV (79.7%, 0.56, 95% CI, 0.41-0.71) between self-collected and clinician-collected samples. The most prevalent hrHPV types were HPV16 and HPV18 in HIV-uninfected and HPV16, HPV51 and HPV59 in HIV-infected women. HIV-infected women with hrHPV infection had multiple hrHPV infections (p = 0.005) and lower CD4 count (p = 0.018). Risk factors for hrHPV infection included being HIV-infected and having five or more sexual partners. Conclusions CVSC had high acceptability and high prevalence of hrHPV types in women living in the Tapajós region, Amazon, Brazil.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2018.08.004

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In that Brazilian sample, a greater proportion of HIV-positive women reported acceptability (97%) than HIV-negative women (84%).

    “A greater proportion of HIV-positive women reported acceptability (97%) than HIV-negative women (84%).”

    From HPV self-sampling for cervical cancer screening: a systematic review of values and preferences (2021) · cites this paper as [60]

    The Results section (‘Acceptability of CVSC’) reports higher acceptance among HIV-infected women than HIV-uninfected women, but gives the figures as 95% (39/41) and 84% (94/112), respectively. The claimed 97% for HIV-positive women does not match the reported acceptability figure. (LLM, conf=0.92)

    Experimental — accuracy not yet measured

  • In a sample of HIV-positive and HIV-negative women from northern Brazil, 87% found cervicovaginal sampling for HPV DNA acceptable.

    “One study surveyed a sample of HIV-positive and HIV-negative women from northern Brazil, reporting that 87% of women found cervicovaginal sampling for HPV DNA acceptable.”

    From HPV self-sampling for cervical cancer screening: a systematic review of values and preferences (2021) · cites this paper as [60]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. [1]de Sanjosé S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX, Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis, Lancet Infect. Dis 7 (2007) 453– 459. doi: 10.1016/S1473-3099(07)70158-5. 17597569 · DOI · Paper page
  2. [2]Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M, Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting, PLoS One. 10 (2015) 1– 17. doi: 10.1371/journal.pone.0143304. PMC4672879 26646541 · DOI
  3. [3]Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A, Global Cancer Statistics, 2012, CA a Cancer J. Clin 65 (2015) 87– 108. doi: 10.3322/caac.21262. 25651787 · DOI
  4. [7]Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M, Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): A community-based randomised controlled trial, Lancet. 378 (2011) 1868– 1873. doi: 10.1016/S0140-6736(11)61522-5. 22051739 · DOI · Paper page
  5. [8]Smith LW, Khurshed F, van Niekerk DJ, Krajden M, Greene SB, Hobbs S, Coldman AJ, Franco EL, Ogilvie GS, Women’s intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program, BMC Public Health. 14 (2014) 1060. doi: 10.1186/1471-2458-14-1060. 25303975 PMC4203923 · DOI
  6. [9]Chen KW, Ouyang YQ, Hillemanns P, Jentschke M, Excellent analytical and clinical performance of a dry self-sampling device for human papillomavirus detection in an urban Chinese referral population, J. Obstet. Gynaecol. Res 42 (2016) 1839– 1845. doi: 10.1111/jog.13132. 27647799 · DOI
  7. [11]Nicol AF, Brunette LL, Nuovo GJ, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Coutinho JR, Vianna-Andrade C, Oliveira NS, Woodham AW, da Silva DM, Kast WM, Secretory leukocyte protease inhibitor expression and high-risk HPV infection in anal lesions of HIV positive patients., J. Acquir. Immune Defic. Syndr 73 (2016) 27– 33. doi: 10.1097/QAI.0000000000001049. 27149102 PMC4981526 · DOI
  8. [13]Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA, The biology and life-cycle of human papillomaviruses, Vaccine. 30 (2012) F55– F70. doi: 10.1016/j.vaccine.2012.06.083. 23199966 · DOI
  9. [14]Igidbashian S, Boveri S, Spolti N, Radice D, Sandri MT, Sideri M, Self-Collected Human Papillomavirus Testing Acceptability: Comparison of Two Self-Sampling Modalities, J. Women’s Heal 20 (2011) 397– 402. doi: 10.1089/jwh.2010.2189. 21351869 · DOI
  10. [15]Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, Furre IE, Johansson MJ, Trope A, Sjoborg KD, Castle PE, Nygard M, Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions, J. Clin. Virol 99–100 (2018) 22– 30. doi: 10.1016/j.jcv.2017.12.008. 29289814 · DOI
  11. [16]Hernández-Márquez C.l., Salinas-Urbina AA, Cruz-Valdez A, Hernández-Girón C, Knowledge of human papilloma virus (HPV) and acceptance of vaginal self-sampling among Mexican woman Clara, Rev. Salud Pública 16 (2014) 697– 708. doi: 10.15446/rsap.v16n5.30071. 26120755 · DOI
  12. [17]Allen-Leigh B, Uribe-Zúñiga P, León-Maldonado L, Brown BJ, Lörincz A, Salmeron J, Lazcano-Ponce E, Barriers to HPV self-sampling and cytology among low-income indigenous women in rural areas of a middle-income setting: A qualitative study, BMC Cancer. 17 (2017) 1– 11. doi: 10.1186/S12885-017-3723-5. 29121873 PMC5679364 · DOI
  13. [18]Alaina J CLT. Brown, New Technologies for Cervical Cancer Screening, Best Pr. Res Clin Obs. Gynaecol 26 (2012) 233– 242. doi: 10.1080/10810730902873927.Testing. PMC3632360 22119058 · DOI
  14. [20]Jentschke M, Chen K, Arbyn M, Hertel B, Noskowicz M, Soergel P, Hillemanns P, Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections, J. Clin. Virol 82 (2016) 46– 50. doi: 10.1016/j.jcv.2016.06.016. 27434147 · DOI
  15. [21]Catarino R, Vassilakos P, Bilancioni A, Bougel S, Boukrid M, Meyer-Hamme U, Petignat P, Accuracy of self-collected vaginal dry swabs using the Xpert human papillomavirus assay, PLoS One. 12 (2017) 1– 12. doi: 10.1371/journal.pone.0181905. PMC5547698 28750015 · DOI
  16. [22]Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial, Lancet Oncol. 11 (2010) 249– 257. doi: 10.1016/S1470-2045(09)70360-2. 20089449 · DOI
  17. [24]Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL, Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test, Gynecol. Oncol 136 (2015) 189– 197. doi: 10.1016/j.ygyno.2014.11.076. 25579108 · DOI
  18. [25]Canfell K, Caruana Μ, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M, Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial, PLoS Med. 14 (2017) 1– 21. doi: 10.1371/journal.pmed.1002388. PMC5604935 28926579 · DOI
  19. [27]and Sylvia Regina Vasconcellos de Aguiar JASQ, Elizabeth Villanova Fabiola, Caricio Martins Luisa, Silva dos Santos Milena, de Paula Maciel Juliana, Fábio Magno Falcão Luiz, Thais Fuzii Hellen, Human Papillomavirus: Prevalence and Factors Associated in Women Prisoners Population From the Eastern Brazilian Amazon, J. Med. Virol 86 (2014) 1528– 33. doi: 10.1002/jmv. 24838771 · DOI
  20. [28]Duarte D, Vieira R, Brito E, Pinheiro M, Monteiro J, Valente M, Ishikawa E, Fuzii H, Sousa M, Prevalence of Human Papillomavirus Infection and Cervical Cancer Screening among Riverside Women of the Brazilian Amazon, Rev. Bras. Ginecol. eObs./RBGO Gynecol. Obstet 39 (2017) 350– 357. doi: 10.1055/S-0037-1604027. PMC10416179 28658700 · DOI
  21. [29]do Amaral JLA, de A MV. Araújo GA da S. Dias, von Ledebur EICF, Quaresma JAS, Fuzii HT, Clinical and epidemiological study of human papillomavirus infection in women with systemic lupus erythematosus in eastern brazilian amazon., Acta Reumatol. Port. 42 (2016) 47– 54. 27750272
  22. [30]da Silva L, Miranda A, Batalha R, Ferreira L, Santos M, Talhari S, High-risk human papillomavirus and cervical lesions among women living with HIV/AIDS in Brazilian Amazon, Brazil, Brazilian J. Infect. Dis 19 (2015) 557– 562. doi: 10.1016/j.bjid.2015.07.001. PMC9425384 26260194 · DOI
  23. [31]Fonseca AJ, Taeko D, Chaves TA, Da Costa Amorim LD, Murari RSW, Miranda AE, Chen Z, Burk RD, Ferreira LCL, HPV infection and cervical screening in socially isolated indigenous women inhabitants of the amazonian rainforest, PLoS One. 10 (2015) 1– 18. doi: 10.1371/journal,pone.0133635. PMC4514624 26207895 · DOI
  24. [32]Ranjeva SL, Baskerville EB, Dukic V, Villa LL, Lazcano-Ponce E, Giuliano AR, Dwyer G, Cobey S, Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity, Proc. Natl. Acad. Sci 114 (2017) 13573– 13578. doi: 10.1073/pnas.1714712114. 29208707 PMC5754802 · DOI
  25. [33]Hanisch RA, Sow PS, Toure M, Dem A, Dembele B, Toure P, Winer RL, Hughes JP, Gottlieb GS, Feng Q, Kiviat NB, Hawes SE, Influence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa, J. Clin. Virol 58 (2013) 696– 702. doi: 10.1016/j.jcv.2013.10.012. 24210330 PMC4059498 · DOI
  26. [34]Teixeira MF, Sabidó M, Leturiondo AL, Ferreira CDO, Torres KL, Benzaken AS, High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas, Virol. J 15 (2018) 36. 29454382 PMC5816532
  27. [35]Firnhaber C, Van Le H, Pettifor A, Schulze D, Michelow P, Sanne IM, Lewis DA, Williamson AL, Allan B, Williams S, Rinas A, Levin S, Smith JS, Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa, Cancer Causes Control. 21 (2010) 433– 443. doi: 10.1007/s10552-009-9475-z. 19949850 PMC2835728 · DOI
  28. [36]Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, Marrazzo JM, Sonder GJB, Schwebke JR, Hoornenborg E, Peeling RW, Philip SS, Low N, Fairley CK, Sexually transmitted infections: challenges ahead, Lancet Infect. Dis 17 (2017) e235– e279. doi: 10.1016/S1473-3099(17)30310-9. 28701272 · DOI
  29. [37]McCloskey JC, Martin Kast W, Flexman JP, McCallum D, French MA, Phillips M, Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions, Papillomavirus Res. 4 (2017) 90– 98. doi: 10.1016/j.pvr.2017.10.004. 29179876 PMC5883243 · DOI

Cited by

Sorted by citations

Authors
Rodrigues, L. L. S., Morgado, M. G., Sahasrabuddhe, V. V., De Paula, V. S., Oliveira, N. S., Chavez-Juan, E., Da Silva, D. M., Kast, W. M., Nicol, A. F., & Pilotto, J. H.
Affiliations
  • Universidade Federal do Oeste do Pará (BR)
  • Fundação Oswaldo Cruz (BR)
  • National Cancer Institute (US)
  • Universidade Federal Fluminense (BR)
  • University of Southern California (US)
  • Instituto Nacional de Infectologia Evandro Chagas (BR)
Corresponding author
  • Rodrigues, Luana L.S.
  • Morgado, Mariza G.
ORCID
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2018-10
Volume
151
Issue
1
Pages
102-110
ISSN
0090-8258 (ISSN-L)
DOI
10.1016/j.ygyno.2018.08.004
PMC
PMC6151287
OpenAlex
W2887169622
Cited by
29
References
4
Citations by year
2026: 3 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 2
FWCI
1.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Gynecologic Oncology (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Arca - Repositório Institucional da Fiocruz (submittedVersion)
Funders
  • CAPES
  • Ministry of Education (88881.131796/2016-01)
  • Programa Estratégico de Apoio a Pesquisa em Saúde
  • Fundação Oswaldo Cruz (FIOCRUZ)/Conselho Nacional de Desenvolvimento Científico e Tecnológico (401810/2015-1)
  • National Institutes of Health (R01 CA074397, P30 CA014089)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
human papillomavirus, high-risk HPV, HIV infection, HPV prevalence, HPV genotypes, HPV16, HPV 18, multiple HPV infection, CD4 count, sexual partners, abnormal cervical cytology, Tapajós region, Amazon
MeSH terms
Adolescent, Adult, Aged, Brazil, Uterine Cervical Neoplasms, Cervix Uteri, Cross-Sectional Studies, DNA, Viral, Female, Genotype, Humans, Mass Screening, Middle Aged, Patient Acceptance of Health Care, Risk Factors, Specimen Handling, Vagina, HIV Infections, Prevalence, CD4 Lymphocyte Count, Papillomaviridae, Papillomavirus Infections, Early Detection of Cancer, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review